TRAVASOL E 522 MG / 100 ML
POTASSIUM PHOSPHATE DIBASIC : 522 MG / 100 ML PHENYLALANINE : 620 MG / 100 ML PROLINE : 420 MG / 100 ML HISTIDINE : 440 MG / 100 ML GLYCINE : 2.08 G / 100 ML ARGININE : 1.04 G / 100 ML THREONINE : 420 MG / 100 ML TYROSINE : 40 MG / 100 ML VALINE : 460 MG / 100 ML ALANINE : 2.08 G / 100 ML MAGNESIUM CHLORIDE : 102 MG / 100 ML SODIUM ACETATE : 680 MG / 100 ML TRYPTOPHAN : 180 MG / 100 ML SODIUM CHLORIDE : 117 MG / 100 ML ISOLEUCINE : 480 MG / 100 ML LEUCINE : 620 MG / 100 ML METHIONINE : 580 MG / 100 ML L-LYSINE (L-LYSINE HYDROCHLORIDE) : 580 MG / 100 ML · DIN 00285528 · BAXTER CORPORATION
Health Canada status: CANCELLED POST MARKET
What is TRAVASOL E?
TRAVASOL E 522 MG / 100 ML contains POTASSIUM PHOSPHATE DIBASIC : 522 MG / 100 ML PHENYLALANINE : 620 MG / 100 ML PROLINE : 420 MG / 100 ML HISTIDINE : 440 MG / 100 ML GLYCINE : 2.08 G / 100 ML ARGININE : 1.04 G / 100 ML THREONINE : 420 MG / 100 ML TYROSINE : 40 MG / 100 ML VALINE : 460 MG / 100 ML ALANINE : 2.08 G / 100 ML MAGNESIUM CHLORIDE : 102 MG / 100 ML SODIUM ACETATE : 680 MG / 100 ML TRYPTOPHAN : 180 MG / 100 ML SODIUM CHLORIDE : 117 MG / 100 ML ISOLEUCINE : 480 MG / 100 ML LEUCINE : 620 MG / 100 ML METHIONINE : 580 MG / 100 ML L-LYSINE (L-LYSINE HYDROCHLORIDE) : 580 MG / 100 ML. It is listed in the Health Canada Drug Product Database under DIN 00285528, held by BAXTER CORPORATION, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 19-Oct-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TRAVASOL E used for?
As an adjunct of a parental nutrition regimen, TRAVASOL E (amino acids WITH electrolytes injection) and TRAVASOL (amino acids injection) products are indicated as a source of amino acids in clinical conditions where enteral nutritional supply is or is expected to be insufficient or impossible in order to offset or prevent nitrogen loss or negative nitrogen balance.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00285528 |
|---|---|
| Brand name | TRAVASOL E |
| Generic / active ingredient | POTASSIUM PHOSPHATE DIBASIC : 522 MG / 100 ML PHENYLALANINE : 620 MG / 100 ML PROLINE : 420 MG / 100 ML HISTIDINE : 440 MG / 100 ML GLYCINE : 2.08 G / 100 ML ARGININE : 1.04 G / 100 ML THREONINE : 420 MG / 100 ML TYROSINE : 40 MG / 100 ML VALINE : 460 MG / 100 ML ALANINE : 2.08 G / 100 ML MAGNESIUM CHLORIDE : 102 MG / 100 ML SODIUM ACETATE : 680 MG / 100 ML TRYPTOPHAN : 180 MG / 100 ML SODIUM CHLORIDE : 117 MG / 100 ML ISOLEUCINE : 480 MG / 100 ML LEUCINE : 620 MG / 100 ML METHIONINE : 580 MG / 100 ML L-LYSINE (L-LYSINE HYDROCHLORIDE) : 580 MG / 100 ML |
| Manufacturer | BAXTER CORPORATION |
| Strength | 522 MG / 100 ML |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Ethical |
| ATC code | B05BA10 COMBINATIONS |
| AHFS class | 40:20.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 19-Oct-2017 |
| Original market date | 1974-12-31 00:00:00 |
How is it stored and handled?
null
How is it supplied?
null
What can be used instead?
Other Canadian products sharing ATC code B05BA10 COMBINATIONS. 22 of 79 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CLINIMIX | 10 G / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02498456 |
| CLINIMIX | 220 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02013932 |
| CLINIMIX | 230 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02013886 |
| CLINIMIX | 310 MG / 100 ML | LIQUID | BAXTER CORPORATION | MARKETED | DIN 02046709 |
| CLINIMIX | 464 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02498464 |
| CLINIMIX | 520 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02013940 |
| CLINIMIX | 690 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02498448 |
| CLINIMIX E | 220 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02013967 |
| CLINIMIX E | 261 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02498413 |
| CLINIMIX E | 290 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02014076 |
Who else supplies COMBINATIONS worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. COMBINATIONS appears in 5 registered pack listings across 2 markets, published on 2 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.